
Tailored nanomedicines to overcome biological barriers for targeted drug delivery

Min-Jun Baek, Pharm.D., Ph.D.

Assistant Professor

Department of Bio and Brain Engineering, College of Engineering

Korea Advanced Institute of Science and Technology

2025.07.02.


Department of Bio and Brain Engineering at KAIST




KAIST, 291 Daehak-ro, Yuseong-gu, **Daejeon**
34141, Republic of Korea



Creating innovative bio-convergent technologies for better human life




Cancer nanomedicines



- Nano-sized particles, designed to deliver therapeutic agents to tumor tissues.

Research field in Bioengineering



Adapted from bioe.uw.edu

❖ Chemical engineering of

1. Organic nanocarriers

- Targeted drug and contrast agent delivery


2. Organic fluorophores

- Early disease diagnosis
- Image-guided surgery & phototherapy



3. Delivery systems for prime editors

- Gene therapy

Controlling in vivo fate of nanoparticles




Off-target effect of NPs




- Many biological barriers remove nanoparticles from the journey.
- Less than 1%** of NPs can reach target (**tumour**).
- More than **99% of NPs** are distributed to **off-target sites**.

Limited extravasation and penetration of NPs in tumor



- The **basement membrane (BM)** prevents the entry of NPs into tumors.
- BM pore size of **~50 nm**.



- **High interstitial fluid pressure (IFP)**
- **Dense extracellular matrix (ECM)**

Tailored nanoparticles to overcome various biological barriers in tumors

Focus I. Renal clearable nanocarriers for tumor selective drug delivery

: Overcoming off-target effect of NPs




Focus II. Photobleaching-harnessing nanoparticles for deep tumor penetration

: Overcoming limited tumor penetration of NPs



Design considerations for renal-clearable nanocarriers



Structure optimization

- Linker length
- Linker position
- Charge

Materials

- Biocompatible
 - Cyclodextrin
 - Amino acid
 - PEG

Size

- 6 ~ 8 nm (renal clearable)
 - Renally clearable
 - Efficient extravasation
 - RES uptake↓


Surface Charge

- Zwitterionic surface
 - Non-specific uptake↓
 - Serum protein binding↓

Tumor selective retention

- Tumor-targeting ligand


Screening of Renal-Clearable CD Derivatives



Schematic view of CD derivatization


1st Screening: Colloidal stability

2nd Screening: Tumor selectivity




Structure-Biodistribution Relationship (SBR)-based tailoring


Tumor targetability of renal-clearable nanocarriers



- **PBA-(ZW)-CD** improved tumor distribution - **14.8-fold** higher **tumor accumulation** compared to (ZW)-CD.




Tumor penetration via transcytosis



Positively charged NPs can penetrate via transcytosis

Problems of positive surface charge




IV administration



- Serum protein aggregation.
- Rapid opsonization.
- High reticuloendothelial system (RES) uptake.
- Nonspecific adsorption to normal cells and tissues.


→ Unsuitable for systemic injection
and tumor targeting

Charge conversion in tumor for penetration




New charge conversion strategy: photobleaching

Laser irradiation time



Idea inspired by photobleaching




Asymmetric degradation

→ From a balanced to an imbalance structure


Photobleaching-mediated charge convertible NPs

Conjugation of NIR fluorophore to the NP surface




Photobleaching-mediated charge conversion



P-ZWNIR NPs [Cyclodextrin nanocarrier + Organic NIR fluorophore]



Fluorescence change upon radiation




Charge conversion




Photobleaching-mediated deep tumor penetration

Tumor penetration of the P-ZWNIR NPs in the HT-29 spheroid model






Delivery cascade and phototherapy mechanism of P-ZWNIR NPs






IV injection $\rightarrow$ Tumor targeting $\rightarrow$ Photobleaching $\rightarrow$ NPs penetration
 $\rightarrow$ Photodynamic therapy

Deep tumor penetration of NPs



Impact of deep tumor penetration on PDT efficacy



PBS
PBS + 808 nm + 660 nm
P-ZWNIR NPs
P-ZWNIR NPs + 808 nm
P-ZWNIR NPs + 660 nm
P-ZWNIR NPs + 808 nm + 660 nm


← **PDT w/o penetration**
← **PDT w penetration**

P-ZWNIR NPs + 808 nm + 660 nm eradicated $\sim 250 \text{ mm}^3$ tumor

Application of highly tumor selective NPs

Renal clearable NPs


ex vivo NIRF imaging at 24 h post injection



Colon cancer


Tumor penetrating NPs

ex vivo NIRF imaging at 8 h post injection



Rectal cancer

Fluorescence image-guided surgery (FGS)





Surgical guidance using intraoperative NIR fluorescence imaging in head and neck surgery with VX2 carcinoma bearing New Zealand White rabbit in buccal area

High tumor selectivity makes image-guided therapy


Fine tuning of chemical structures

*Nanocarrier + Fluorophore




P-ZWNIR NPs (zwitterionic)

NIR laser irradiation (808 nm)



Charge-converted NPs (cationic)

Fluorescence image-guided phototherapy



One-shot laser therapy → Complete remission

Current research and interests

Research fields

Small chemical drug delivery

Chemical engineering of nanomaterials

- Renal or hepatobiliary clearable materials
- Photobleaching materials

Chemical engineering of organic fluorophores

- Photobleaching materials
- Anti-photobleaching materials



Potential fields for collaboration

Biopharmaceutical delivery

- RNA therapeutics
- Prime editors: base edit

Developing delivery technique

- Light (NIR-I or NIR-II)
- Ultrasound

Current research and interests

- ❖ Utilizing cyclodextrin derivatives to modulate biodistribution of mRNA LNPs

Lipid nanoparticles (LNPs) + CD derivatives


➔ **Hybrid LNP**

Conventional mRNA-LNP


MC3LNP

Spleen-targeted Hybrid LNP

Candidate#B12



vs



High




Low

Unpublished data

Current research and interests

- ❖ Expanding the application of the **phototheranostics** to Intractable cancer such as **peritoneal metastasis** and **pancreatic cancer**.



Q&A



Acknowledgment



Seoul National University, College of Pharmacy

- ❖ Prof. Dae-Duk Kim
 - Dr. Ju-Hwan Park (Dong-A Pharmaceutical Co., Ltd.)
 - Dr. Duy-Thuc Nguyen (The University of Chicago)
 - Dr. Tae-Kwang Kim (Ildong Pharmacautical Co.,Ltd.)
 - Dahan Kim
 - Piljae Song
- ❖ Prof. Jae-Young Lee
 - Dr. So-Yeol Yoo
 - Sang Min Lee



Harvard Medical School and Massachusetts General Hospital Gordon Center for Medical Imaging, BENMD program

- ❖ Prof. Hak Soo Choi and BENMD fellows

